Amgen Inc (AMGN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Amgen reported revenue of $36.75B, up 10.0% from $33.42B the year before. Net income was $7.71B (a 21.0% net margin), or $14.23 per diluted share. Gross margin was 67.2% and operating margin was 24.7%. Operating activities generated $9.96B of cash, leaving $8.10B of free cash flow. At fiscal year end, Amgen held $90.59B in total assets against $81.93B in total liabilities, including $9.13B of cash and equivalents.
Open the full interactive Amgen financials → Quarterly statements, key ratios, valuation history and price charts.
Amgen Key Stats
| Share Price | $412.84 |
|---|---|
| Market Cap | $224.58B |
| P/E Ratio | 29.0 |
| Revenue YoY Growth | +10.0% |
| 52-Week Range | $283.30 – $444.12 |
| Shares Outstanding | 540.0 million (basic, 2026 Q2) |
Amgen Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| Cost of Goods Sold | $6.16B | $6.45B | $6.41B | $8.45B | $12.86B | $12.04B |
| Gross Profit | $19.27B | $19.52B | $19.92B | $19.74B | $20.57B | $24.71B |
| Operating Income | $9.14B | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B |
| Pre-Tax Income | $8.13B | $6.70B | $7.35B | $7.86B | $4.61B | $8.98B |
| Income Tax | $869.0M | $808.0M | $794.0M | $1.14B | $519.0M | $1.26B |
| Net Income | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B |
| Diluted EPS | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
Amgen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.56B | $9.87B | $8.62B | $10.05B |
| Net Income | $3.22B | $1.33B | $1.82B | $2.38B |
| Diluted EPS | $5.93 | $2.46 | $3.34 | $4.37 |
Amgen Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.27B | $7.99B | $7.63B | $10.94B | $11.97B | $9.13B |
| Current Assets | $21.14B | $19.39B | $22.19B | $30.33B | $29.03B | $29.06B |
| Total Assets | $62.95B | $61.16B | $65.12B | $97.15B | $91.84B | $90.59B |
| Current Liabilities | $11.65B | $12.18B | $15.69B | $18.39B | $23.10B | $25.49B |
| Total Long-Term Debt | $32.99B | $33.31B | $38.95B | $64.61B | $60.10B | $54.60B |
| Total Liabilities | $53.54B | $54.47B | $61.46B | $90.92B | $85.96B | $81.93B |
| Shareholders' Equity | $9.41B | $6.70B | $3.66B | $6.23B | $5.88B | $8.66B |
Amgen Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $10.50B | $9.26B | $9.72B | $8.47B | $11.49B | $9.96B |
| Cash From Investing | -$5.40B | $733.0M | -$6.04B | -$26.20B | -$1.05B | -$1.94B |
| Cash From Financing | -$4.87B | -$8.27B | -$4.04B | $21.05B | -$9.41B | -$10.86B |
| Free Cash Flow | $9.89B | $8.38B | $8.79B | $7.36B | $10.39B | $8.10B |
Figures from Amgen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Amgen financials page for every line item.
Amgen Company Profile
| Ticker | AMGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Thousand Oaks, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000318154 |
Frequently Asked Questions
What was Amgen's revenue in fiscal 2025?
Amgen (AMGN) reported revenue of $36.75B for fiscal 2025.
What is Amgen's annual revenue history?
Amgen's annual revenue by fiscal year: 2020: $25.42B; 2021: $25.98B; 2022: $26.32B; 2023: $28.19B; 2024: $33.42B; 2025: $36.75B.
What was Amgen's net income in fiscal 2025?
Amgen reported net income of $7.71B for fiscal 2025.
What was Amgen's earnings per share (EPS) in fiscal 2025?
Amgen's diluted EPS was $14.23 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Amgen generate in fiscal 2025?
Amgen generated $8.10B of free cash flow in fiscal 2025.
What was Amgen's revenue last quarter?
In its most recent reported quarter (2026 Q2), Amgen reported revenue of $10.05B.
How much debt does Amgen have?
Amgen reported $54.60B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Amgen are outstanding?
Amgen reported a weighted average of 540.0 million basic shares outstanding in 2026 Q2.
What is Amgen's market cap?
Based on its latest closing price, Amgen (AMGN) has a market capitalization of about $224.58B.
When does Amgen's fiscal year end?
Amgen's fiscal year end, as registered with the SEC, is December 31.
Where is Amgen headquartered?
Amgen lists its business address in Thousand Oaks, California in its SEC filings.